Dr Reddy's Laboratories
Sputnik V clinical trial is about to begin: Saumen Chakraborty, CFO, Dr Reddy’s Laboratories
Fri, Oct 30, 2020
Dr Reddy’s has launched 20 products so far in this financial year, says Saumen Chakraborty, Chief Financial Officer, Dr Reddy's Laboratories. During a chat with Swati Khandelwal, Zee Business, Chakraborty said, the trial of sputnik about to start and we have around 100 patients in Phase-II and 1,500 in phase-III.
More >
Trials of Russian Sputnik-V vaccine may end as early as March: Dr Reddy''s
Wed, Oct 28, 2020
Drugmaker Dr Reddy`s Laboratories Ltd on Wednesday rolled out a preliminary timeline for the India trials of Russia`s coronavirus vaccine candidate, with the late-stage expected to be completed by as early as March 2021.
More >
Dr Reddy's seeks DCGI nod for conducting phase-3 clinical trial of Russian COVID-19 vaccine Sputnik V
Sat, Oct 03, 2020
The Hyderabad-based Dr Reddy's Laboratories has applied to the Drugs Controller General of India for permission to conduct phase-3 human clinical trials of the Russian vaccine Sputnik V against COVID-19 in India, sources said.
More >
Dr Reddy's Share price skyrockets near 13 pct; stock market experts suggest this strategy to mint money
Fri, Sep 18, 2020
Dr Reddy's share price has skyrocketed around 13 per cent in the intraday trade session. Dr Reddy's share price today shot up over Rs 625 to hit Rs 5,423 per share mark today.
More >
Stocks in Focus on September 18: Dr Reddy's, Cipla, Lupin, Happiest Minds Technologies to HDFC Bank; here are expected newsmakers of the day
Fri, Sep 18, 2020
Stocks in Focus on September 18: Dr Reddy's, Cipla, Lupin, Happiest Minds Technologies, HDFC Bank, etc. are expected newsmakers throughout the intraday trade session.
More >
Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018
Mon, Dec 31, 2018
The sector has been volatile throughout the year due to constant news flow in the markets. Some giants of the sector witnessed objections over their manufacturing plants and medicine pricing in the U.S. markets.
More >
Big blow to Dr Reddy's over opioid addiction treatment block in US; share price tanks a whopping 11%
Mon, Jul 16, 2018
Analysts at Jefferies believe injunction is a negative surprise for Dr Reddy’s and risks for FY20-22 EPS estimates have increased after the ruling. retain “underperform”, cuts TP to 1,850 rupees from 1,910 rupees
More >
Dr Reddy's last day on Sensex; stock rallies 20% in 8 sessions
Fri, Jun 15, 2018
Dr Reddy's share price gained as much as 20 per cent in the last 8 sessions, thanks to a renewed optimism on the sector. Nifty Pharma index itself gained 14 per cent during the same period. In Friday's trade, Nifty Pharma was the top sectoral gainer, led by gains in Dr Reddy's.
More >
Dr Reddy's Q4 net profit rises by 319%
Fri, May 12, 2017
GV Prasad, Co-Chairman and CEO of Dr Reddy's Laboratories said, “FY17 has been challenging year due to lack of new product approvals for the US market. However, our other geoghraphies delivered good performance with several new product launches.”
More >
Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore
Sat, Feb 04, 2017
GV Prasad, Co-chairman of Dr Reddy's Laboratories said, "Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&A cost across all our business."
More >
